Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Multiplex Bio Purchase Agreement governs the previously disclosed transaction.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Multiplex Bio Purchase Agreement governs the previously disclosed transaction
- Terms incorporated by reference from July 28, 2026 Form 8-K, amended July 29, 2026
- Investors should review Exhibit 2.1 for definitive purchase terms and obligations
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure concerns proposed Business disposition and Merger involving Treeline, GMT Venture and Element
- Transactions remain subject to stockholder approvals, closing conditions and potential competing proposals
- Key risks include termination fees, litigation, management distraction, retention challenges and Nasdaq listing failure
- Company filed Form S-4 July 20, 2026, amended September 9, 2026; proxy/prospectus materials govern investor voting decisions
Item EX-99.1 · Exhibit EX-99.1
- Multiplex Bio sale terminated; Mass Cytometry business sold to GMT Venture’s Element Biosystems for $5.5 million cash
- Avoiding Multiplex’s required $10 million working-capital loan improves Treeline merger exchange-ratio net cash by approximately $15 million
- Element transaction and Treeline merger both expected to close by end of 2026, subject to stockholder approval and customary conditions
- Sale transfers CyTOF, Hyperion, and Maxpar platforms while preserving customer and team continuity under new ownership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.